ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01681992
Recruitment Status : Completed
First Posted : September 10, 2012
Results First Posted : August 17, 2018
Last Update Posted : August 17, 2018
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck & Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).

Condition or disease Intervention/treatment Phase
Measles Mumps Rubella Biological: Priorix Biological: M-M-R II Biological: Varivax Biological: Havrix Biological: Prevnar 13 Phase 3

Detailed Description:
This trial is a Phase IIIA, randomized, observer-blind, controlled, multi-center, multi-country study with four parallel groups. This study will evaluate the immunogenicity and safety of GSK Biologicals' trivalent investigational MMR vaccine (referred to as Inv_MMR vaccine, throughout this document) in contrast to the US standard of care comparator vaccine (M-M-R II, Merck and Co., Inc., referred to as Com_MMR throughout this document) in children during their second year of life. The first dose of this two-dose study is designed to establish the end of shelf-life potency of Inv_MMR vaccine. The Inv_MMR vaccine will be given as one of two lots; one of a minimum potency, designated Inv_MMR_Min; and the other at a mid-range or medium potency designated Inv_MMR_Med to two groups. The second dose for both of these Inv_MMR groups will have a potency within the release range of the marketed vaccine. The Com_MMR vaccine will consist of two lots designated Com_MMR_L1 and Com_MMR_L2 and will be analyzed as pooled lots within the study. The first MMR vaccine dose will be co-administered with Varivax, Havrix and (in the US sub-cohort only) Prevnar 13 which are routinely administered to children of this age in the US.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4538 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety Study of GSK Biologicals' Priorix Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life
Actual Study Start Date : October 10, 2012
Actual Primary Completion Date : February 3, 2015
Actual Study Completion Date : August 18, 2015


Arm Intervention/treatment
Experimental: Inv_MMR_Min Group
Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a minimum potency lot (Inv_MMR_Min), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
Biological: Priorix
Subjects receive one dose of either minimum (Inv_MMR_Min) or medium (Inv_MMR_Med) potency lot at Day 0 and a dose of separate potency lot (Inv_MMR_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
Other Names:
  • GSK Biologicals' live attenuated measles
  • mumps
  • rubella vaccine

Biological: Varivax
Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
Other Names:
  • Merck & Co.
  • Inc.'s varicella virus vaccine
  • live

Biological: Havrix
Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
Other Names:
  • GSK Biologicals' hepatitis A vaccine
  • inactivated

Biological: Prevnar 13
US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
Other Name: Pfizer Inc.'s pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)

Experimental: Inv_MMR_Med Group
Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
Biological: Priorix
Subjects receive one dose of either minimum (Inv_MMR_Min) or medium (Inv_MMR_Med) potency lot at Day 0 and a dose of separate potency lot (Inv_MMR_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
Other Names:
  • GSK Biologicals' live attenuated measles
  • mumps
  • rubella vaccine

Biological: Varivax
Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
Other Names:
  • Merck & Co.
  • Inc.'s varicella virus vaccine
  • live

Biological: Havrix
Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
Other Names:
  • GSK Biologicals' hepatitis A vaccine
  • inactivated

Biological: Prevnar 13
US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
Other Name: Pfizer Inc.'s pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)

Active Comparator: Com_MMR Group
Subjects receive one dose of M-M-R II (Com_MMR) vaccine (Lot 1 or Lot 2), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
Biological: M-M-R II
Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.
Other Names:
  • Merck & Co.
  • Inc.'s measles
  • mumps
  • rubella virus vaccine
  • live

Biological: Varivax
Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
Other Names:
  • Merck & Co.
  • Inc.'s varicella virus vaccine
  • live

Biological: Havrix
Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
Other Names:
  • GSK Biologicals' hepatitis A vaccine
  • inactivated

Biological: Prevnar 13
US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
Other Name: Pfizer Inc.'s pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)




Primary Outcome Measures :
  1. Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value (by Enzyme-linked Immunosorbent Assay [ELISA]) [ Time Frame: At Day 42 ]
    For measles virus, a seroresponse was defined as post-vaccination anti-measles virus antibody concentration equal or above [≥] 200 mIU/mL (ELISA) among subjects who were seronegative (antibody concentration less than [<] 150 mIU/mL) before dose 1. Criteria to demonstrate an acceptable immune response of Inv_MMR_Min/Inv_MMR_Med vaccine in terms of seroresponse rate for measles virus at Day 42: The lower limit of the two-sided 97.5% CI for the seroresponse rate of Inv_MMR_Min/Inv_MMR_Med was to be ≥ 90% for antibodies to measles virus.

  2. Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA) [ Time Frame: At Day 42 ]
    For mumps virus, a seroresponse was defined as post-vaccination anti-mumps virus antibody concentration ≥ 10 EU/mL (ELISA) among subjects who were seronegative (antibody concentration < 5 EU/mL) before dose 1. Criteria to demonstrate an acceptable immune response of Inv_MMR_Min/Inv_MMR_Med vaccine in terms of seroresponse rate for mumps virus at Day 42: The lower limit of the two-sided 97.5% CI for the seroresponse rate of Inv_MMR_Min/Inv_MMR_Med was to be ≥ 90% for antibodies to mumps virus.

  3. Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value (by Plaque Reduction Neutralization Test [PRNT]) [ Time Frame: At Day 42 ]
    For mumps virus as measured by PRNT, a seroresponse was defined as post-vaccination anti-mumps virus antibody concentration ≥ 4 End point Dilution 50% (ED50) (PRNT) among subjects who were seronegative (antibody concentration < 2.5 ED50) before dose 1.

  4. Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA) [ Time Frame: At Day 42 ]
    For rubella virus, a seroresponse was defined as post-vaccination anti-rubella virus antibody concentration ≥ 10 IU/mL (ELISA) among subjects who were seronegative (antibody concentration < 4 IU/mL) before dose 1. Criteria to demonstrate an acceptable immune response of Inv_MMR_Min/Inv_MMR_Med vaccine in terms of seroresponse rate for rubella virus at Day 42: The lower limit of the two-sided 97.5% CI for the seroresponse rate of Inv_MMR_Min/Inv_MMR_Med was to be ≥ 90% for antibodies to mumps virus.

  5. Anti-measles Virus Antibody Concentrations (by ELISA) [ Time Frame: At Day 42 ]
    Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs) in mIU/mL.

  6. Anti-mumps Virus Antibody Concentrations (by ELISA) [ Time Frame: At Day 42 ]
    Antibody concentrations were expressed as GMCs in EU/mL.

  7. Anti-mumps Virus Antibody Concentrations (by PRNT) [ Time Frame: At Day 42 ]
    Antibody concentrations were expressed as Geometric Mean Titers (GMTs).

  8. Anti-rubella Virus Antibody Concentrations (by ELISA) [ Time Frame: At Day 42 ]
    Antibody concentrations were expressed as GMCs in IU/mL.


Secondary Outcome Measures :
  1. Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA) [ Time Frame: At Day 84 ]
    For measles virus, a seroresponse was defined as post-vaccination anti-measles virus antibody concentration ≥ 200 mIU/mL (ELISA) among subjects who were seronegative (antibody concentration < 150 mIU/mL) before dose 1.

  2. Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA) [ Time Frame: At Day 84 ]
    For mumps virus, a seroresponse was defined as post-vaccination anti-mumps virus antibody concentration ≥ 10 EU/mL (ELISA) among subjects who were seronegative (antibody concentration < 5 EU/mL) before dose 1.

  3. Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA) [ Time Frame: At Day 84 ]
    For rubella virus, a seroresponse was defined as post-vaccination anti-rubella virus antibody concentration ≥ 10 IU/mL (ELISA) among subjects who were seronegative (antibody concentration < 4 IU/mL) before dose 1.

  4. Anti-measles Virus Antibody Concentrations (by ELISA) [ Time Frame: At Day 84 ]
    Antibody concentrations were expressed as GMCs in mIU/mL.

  5. Anti-mumps Virus Antibody Concentrations (by ELISA) [ Time Frame: At Day 84 ]
    Antibody concentrations were expressed as GMCs in EU/mL.

  6. Anti-rubella Virus Antibody Concentrations (by ELISA) [ Time Frame: At Day 84 ]
    Antibody concentrations were expressed as GMCs in IU/mL.

  7. Number of Subjects With Any Solicited Local Adverse Events (AEs) Post Dose 1 [ Time Frame: During the 4-day (Days 0-3) post-vaccination period ]
    Assessed solicited local AEs were pain, redness and swelling. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

  8. Number of Subjects With Any Solicited Local AEs Post Dose 2 [ Time Frame: During the 4-day (Days 0-3) post-vaccination period ]
    Assessed solicited local AEs were pain, redness and swelling. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

  9. Number of Subjects With Any Solicited General AEs Post Dose 1 [ Time Frame: During the 15-day (Days 0-14) post-vaccination period ]
    Assessed solicited general AEs were drowsiness, irritability/fussiness and loss of appetite. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

  10. Number of Subjects Reporting Any Fever Post Dose 1 [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    Any fever = Fever (axillary) ≥ 38°C.

  11. Number of Subjects Reporting Any Fever Post Dose 2 [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    Any fever = Fever (axillary) ≥ 38°C.

  12. Number of Subjects Reporting Any Rash Post Dose 1 [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    Assessed were any localized or generalized rash, rash with fever, varicella-like rash and measles/rubella-like rash. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

  13. Number of Subjects Reporting Any Rash Post Dose 2 [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    Assessed were any localized or generalized rash, rash with fever, varicella-like rash and measles/rubella-like rash. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

  14. Number of Subjects Reporting Any MMR Specific Solicited General AEs Post Dose 1 [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    Assessed MMR specific solicited general AEs were any suspected signs of meningism including febrile convulsions and parotid/salivary gland swelling. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

  15. Number of Subjects Reporting Any MMR Specific Solicited General AEs Post Dose 2 [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    Assessed MMR specific solicited general AEs were any suspected signs of meningism including febrile convulsions and parotid/salivary gland swelling. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

  16. Number of Subjects Reporting Any Unsolicited AES Post Dose 1 [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    Unsolicited AE was defined as any AE reported in reported in addition to those solicited during the clinical study and any solicited AE with onset outside the specified period of follow-up for solicited AEs. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

  17. Number of Subjects Reporting Any Unsolicited AES Post Dose 2 [ Time Frame: During the 43-day (Days 0-42) post-vaccination period ]
    Unsolicited AE was defined as any AE reported in reported in addition to those solicited during the clinical study and any solicited AE with onset outside the specified period of follow-up for solicited AEs. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

  18. Number of Subjects Reporting Any AEs of Specific Interest [ Time Frame: From Day 0 through the end of the study (Day 222) ]
    AEs of specific interest included new onset chronic disease (NOCD) (e.g., autoimmune disorders, asthma, type I diabetes, vasculitis, celiac disease, conditions associated with sub-acute or chronic thrombocytopenia and allergies) and AEs prompting emergency room (ER) visits.

  19. Number of Subjects Reporting Any Serious Adverse Events (SAEs) [ Time Frame: From Day 0 through the end of the study (Day 222) ]
    SAEs assessed include any untoward medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Months to 15 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female child between 12 and 15 months of age at the time of vaccination.
  • The investigator believes that the parent(s) or Legally Acceptable Representative(s) (LAR(s)) of the child, can, and will comply with the requirements of the protocol.
  • Written informed consent obtained from the parent(s)/LAR(s) of the child.
  • Child is in stable health as determined by investigator's clinical examination and assessment of child's medical history.

For US children only:

• Child that previously received a 3-dose series of Prevnar 13 with last dose at least 60 days prior to study entry.

Exclusion Criteria:

  • Child in care.
  • Use of any investigational or non-registered product other than the study vaccine(s) during the period starting 30 days before the day of study vaccination or planned use during the entire study period.
  • Concurrently participating in another clinical study, in which the child has been or will be exposed to an investigational or a non-investigational product. Chronic administration of immunosuppressants, or other immune-modifying drugs during the period starting 180 days prior to the first vaccine dose or any planned administration of immunosuppressive and immune-modifying drugs during the entire study.

    • Inhaled and topical steroids are allowed.
  • Planned administration / administration of a vaccine not foreseen by the study protocol during the period starting 30 days prior to study vaccination at Visit 1 and ending at Visit 2 (or ending at Visit 3 for the US post-dose 2 sub-cohort). Please Note:

    • Inactivated influenza (Flu) vaccine and Haemophilus influenzae type b conjugate vaccine (Hib) vaccines may be given at any time during the study, including the day of study vaccination (Flu and Hib vaccines must be administered at a different location than the study vaccine/s).
    • Any age appropriate vaccine may be given starting at Visit 2 (or starting at Visit 3 for the US post-dose 2 sub-cohort), and anytime thereafter.
  • Administration of immunoglobulins and/or any blood products during the period starting 180 days prior to study vaccination at Visit 1 or planned administration from the date of vaccination through the immunogenicity evaluation at Visit 2, or at Visit 3 for the US post-dose 2 sub-cohort.
  • History of measles, mumps, rubella, varicella/zoster and/or hepatitis A diseases.
  • Known exposure to measles, mumps, rubella and/or varicella/zoster during the period starting 30 days prior to the first study vaccination.
  • Previous vaccination against measles, mumps, rubella, hepatitis A and/or varicella virus.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including hypersensitivity to neomycin, latex or gelatin.
  • Blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems.
  • Acute disease at the time of enrollment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. Fever is defined as temperature ≥38°C/100.4°F by any age appropriate route. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection without fever.
  • Active untreated tuberculosis based on medical history.
  • Any other condition which, in the opinion of the Investigator, prevents the child from participating in the study.

For US children only:

• A child that previously received a fourth dose of any pneumococcal conjugate vaccine.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01681992


  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Birmingham, Alabama, United States, 35205
United States, Arizona
GSK Investigational Site
Phoenix, Arizona, United States, 85012
GSK Investigational Site
Phoenix, Arizona, United States, 85032
United States, Arkansas
GSK Investigational Site
Jonesboro, Arkansas, United States, 72401
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
United States, California
GSK Investigational Site
Anaheim, California, United States, 92805
GSK Investigational Site
Long Beach, California, United States, 90813
GSK Investigational Site
West Covina, California, United States, 91790
United States, Florida
GSK Investigational Site
Altamonte Springs, Florida, United States, 32701
GSK Investigational Site
Miami Lakes, Florida, United States, 33014
GSK Investigational Site
Miami, Florida, United States, 33184
GSK Investigational Site
Naples, Florida, United States, 34102
GSK Investigational Site
Tampa, Florida, United States, 33606
United States, Indiana
GSK Investigational Site
Muncie, Indiana, United States, 47304-5547
GSK Investigational Site
New Albany, Indiana, United States, 47150
United States, Iowa
GSK Investigational Site
West Des Moines, Iowa, United States, 50265
United States, Kansas
GSK Investigational Site
Wichita, Kansas, United States, 67205
United States, Kentucky
GSK Investigational Site
Louisville, Kentucky, United States, 40207
GSK Investigational Site
Nicholasville, Kentucky, United States, 40356
United States, Maryland
GSK Investigational Site
Annapolis, Maryland, United States, 21401
GSK Investigational Site
Baltimore, Maryland, United States, 21201
GSK Investigational Site
Frederick, Maryland, United States, 21702
United States, Missouri
GSK Investigational Site
Kansas City, Missouri, United States, 64108
United States, Nebraska
GSK Investigational Site
Bellevue, Nebraska, United States, 68123
GSK Investigational Site
Fremont, Nebraska, United States, 68025
GSK Investigational Site
Lincoln, Nebraska, United States, 68504
GSK Investigational Site
Lincoln, Nebraska, United States, 68505
GSK Investigational Site
Omaha, Nebraska, United States, 68131
United States, North Carolina
GSK Investigational Site
Clyde, North Carolina, United States, 28721
GSK Investigational Site
Holly Springs, North Carolina, United States, 27540
United States, Ohio
GSK Investigational Site
Cleveland, Ohio, United States, 44121
GSK Investigational Site
Dayton, Ohio, United States, 45406
GSK Investigational Site
Dayton, Ohio, United States, 45414
GSK Investigational Site
Toledo, Ohio, United States, 43606
GSK Investigational Site
Youngstown, Ohio, United States, 44505
GSK Investigational Site
Youngstown, Ohio, United States, 44514
United States, Oregon
GSK Investigational Site
Gresham, Oregon, United States, 97030
United States, Pennsylvania
GSK Investigational Site
Indiana, Pennsylvania, United States, 15701
GSK Investigational Site
Johnstown, Pennsylvania, United States, 15904
United States, South Carolina
GSK Investigational Site
Charleston, South Carolina, United States, 29406
GSK Investigational Site
Charleston, South Carolina, United States, 29414
United States, Texas
GSK Investigational Site
Houston, Texas, United States, 77087
GSK Investigational Site
Waco, Texas, United States, 76710
United States, Utah
GSK Investigational Site
Layton, Utah, United States, 84041
GSK Investigational Site
Saint George, Utah, United States, 84790
GSK Investigational Site
Springville, Utah, United States, 84663
United States, Virginia
GSK Investigational Site
Midlothian, Virginia, United States, 23113
GSK Investigational Site
Richmond, Virginia, United States, 23223
GSK Investigational Site
Richmond, Virginia, United States, 23294
United States, Washington
GSK Investigational Site
Ellensburg, Washington, United States, 98926
Czechia
GSK Investigational Site
Benesov, Czechia, 256 01
GSK Investigational Site
Chlumec nad Cidlinou, Czechia, 50351
GSK Investigational Site
Decin, Czechia, 405 01
GSK Investigational Site
Jindrichuv Hradec, Czechia, 37701
GSK Investigational Site
Kladno, Czechia, 272 01
GSK Investigational Site
Liberec, Czechia, 46015
GSK Investigational Site
Lipnik nad Becvou, Czechia, 75131
GSK Investigational Site
Nachod, Czechia, 547 01
GSK Investigational Site
Odolena voda, Czechia, 25070
GSK Investigational Site
Ostrava - Poruba, Czechia, 70800
GSK Investigational Site
Pardubice, Czechia, 532 03
GSK Investigational Site
Plzen, Czechia, 305 99
GSK Investigational Site
Praha 6, Czechia, 1600
Finland
GSK Investigational Site
Helsinki, Finland, 00100
GSK Investigational Site
Helsinki, Finland, 00930
GSK Investigational Site
Jarvenpaa, Finland, 04400
GSK Investigational Site
Oulu, Finland, 90220
GSK Investigational Site
Tampere, Finland, 33100
GSK Investigational Site
Turku, Finland, 20520
Malaysia
GSK Investigational Site
Kuala Terengganu, Malaysia, 20400
GSK Investigational Site
Kuching, Malaysia, 93586
GSK Investigational Site
Sibu, Malaysia, 96000
Puerto Rico
GSK Investigational Site
Barceloneta, Puerto Rico, 00617
GSK Investigational Site
Cidra, Puerto Rico, 00739
GSK Investigational Site
Guayama, Puerto Rico, 00784
GSK Investigational Site
Ponce, Puerto Rico, 00716
GSK Investigational Site
San Juan, Puerto Rico, 00936-5067
GSK Investigational Site
Santurce, Puerto Rico, 00912
Spain
GSK Investigational Site
Antequera/Málaga, Spain, 29200
GSK Investigational Site
Barcelona, Spain, 08042
GSK Investigational Site
Centelles (Barcelona), Spain, 08540
GSK Investigational Site
L'Eliana, Valencia, Spain, 46183
GSK Investigational Site
Manlleu, Spain, 08560
GSK Investigational Site
Quart De Poblet, Valencia, Spain, 46930
GSK Investigational Site
Santiago de Compostela, Spain, 15706
GSK Investigational Site
Sevilla, Spain, 41014
GSK Investigational Site
Valencia, Spain, 46020
GSK Investigational Site
Valencia, Spain, 46024
GSK Investigational Site
Valencia, Spain, 46200
GSK Investigational Site
Vic, Spain, 08500
Thailand
GSK Investigational Site
Bangkok, Thailand, 10330
GSK Investigational Site
Bangkok, Thailand, 10400
GSK Investigational Site
Bangkok, Thailand, 10700
GSK Investigational Site
Chiang mai, Thailand, 50200
GSK Investigational Site
Patumtani, Thailand, 12121
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01681992     History of Changes
Other Study ID Numbers: 115649
2011-004905-26 ( EudraCT Number )
First Posted: September 10, 2012    Key Record Dates
Results First Posted: August 17, 2018
Last Update Posted: August 17, 2018
Last Verified: July 2018

Keywords provided by GlaxoSmithKline:
Safety
Measles, mumps and rubella diseases
Immunogenicity

Additional relevant MeSH terms:
Measles
Rubella
Mumps
Morbillivirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases
Rubivirus Infections
Togaviridae Infections
Rubulavirus Infections
Parotitis
Parotid Diseases
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Vaccines
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs